A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

Number of Participants With at Least an Improvement of Fibrosis ≥1 Stage Without Worsening of Steatohepatitis at Week 52

Worsening of steatohepatitis is defined as increase in non-alcoholic fatty liver disease (NAFLD) Activity Score (NAS) for ballooning, inflammation, or steatosis

Time frame: Week 52

Number of Participants With Resolution of Steatohepatitis Without Worsening of Fibrosis at Week 52

Resolution of steatohepatitis is defined as total absence of ballooning (score=0) and absent or mild inflammation (score 0 to 1). Worsening of fibrosis is defined as progression of fibrosis by ≥1 stage.

Time frame: Week 52

Time to First Occurrence of Disease Progression

Final analysis of the time to first occurrence of disease progression will be measured by a composite of protocol-specified clinical events

Time frame: Up to 5 years